Question 1

Can I get life insurance with rheumatoid arthritis?

Accepted Answer

Yes. Rheumatoid arthritis is broadly insurable when well-controlled. RA in remission or low disease activity with minimal joint damage can qualify for standard or near-standard rates at many major carriers. Higher disease activity, significant joint damage, or RA-related systemic complications such as interstitial lung disease or cardiovascular involvement result in higher table ratings.

Question 2

Do biologic medications for RA hurt my life insurance application?

Accepted Answer

Biologics such as TNF inhibitors or JAK inhibitors are a signal of more severe RA requiring more aggressive treatment, which underwriters note. However, a good treatment response on biologics — demonstrated by low disease activity and minimal joint damage — can still result in Preferred or standard rates at many carriers. The response to treatment matters more than the specific medication used.

Question 3

What RA factors most affect underwriting outcomes?

Accepted Answer

The most important factors are current disease activity (DAS28 score), degree of joint damage and functional disability, medication regimen, and the presence of extra-articular complications. RA limited to the joints with low disease activity and no cardiovascular or pulmonary involvement is the most favorable presentation. Significant erosive disease, functional impairment, or RA-related lung disease substantially restricts options.

Question 4

Does seropositivity (positive RF or anti-CCP) affect my life insurance rates?

Accepted Answer

Seropositive RA — positive rheumatoid factor or anti-CCP antibodies — is generally associated with more aggressive disease and may be viewed slightly less favorably than seronegative RA at the same disease activity level. However, current disease activity, functional status, and the absence of extra-articular complications are more influential factors than seropositivity alone.

Question 5

Can I get Preferred rates with rheumatoid arthritis?

Accepted Answer

Preferred rates are achievable for RA applicants in documented remission or low disease activity, on methotrexate or hydroxychloroquine monotherapy, with minimal joint damage and no extra-articular complications. Applicants on biologic therapy with good response may also achieve Preferred at competitive carriers. The key factors are documented low disease activity scores and a clean overall health profile.

RA Profile	Typical Rating	Best Achievable	Notes
Remission or low activity, methotrexate or hydroxychloroquine	Standard to Table 2	Standard at many carriers	Well-controlled RA is widely insurable at favorable rates
Low-moderate activity, biologic therapy, minimal damage	Table 2–4	Table 2 at competitive carriers	Biologics add rating but remain insurable with good response
Moderate-high activity, significant joint damage	Table 4–8	Table 4	Limited options; carrier selection important
RA with ILD, cardiovascular involvement, or major disability	Table 8–10 or decline	Very limited options	Extra-articular complications severely restrict the field

Life Insurance with Rheumatoid Arthritis | RA Life Insurance | High Risk

What Underwriters Evaluate for Rheumatoid Arthritis

RA Profile: General Underwriting Outlook

Have Rheumatoid Arthritis? Let’s Find Your Best Rate.

Browse All High-Risk Conditions

Ready to Protect What Matters Most?